Sangamo Therapeutics SGMO Coverage Launched by StockNews.com

StockNews.com has recently started covering Sangamo Therapeutics, Inc. SGMO, a clinical-stage biotechnology firm committed to developing genomic medicines that profoundly change patients' lives through gene therapy, cell therapy, genome editing, and genome regulation. On Friday, the research analysts issued a report where they have assigned a "sell" rating to the SGMO stock, marking a critical moment for the company based in Brisbane, California.

Diverse Analyst Opinions on SGMO

Various equity research analysts have expressed their views on SGMO. For instance, Wells Fargo & Company reaffirmed an "equal weight" rating with a $1.00 price target. Conversely, Barclays adjusted its price target from $11.00 down to $9.00 while maintaining an "overweight" stance. HC Wainwright reduced its price target from $5.00 to $3.00, continuing to recommend a "buy" rating. Truist Financial has maintained a "hold" rating, emphasizing a cautious approach. Wedbush also adjusted its price target downward from $16.00 to $10.00, yet still suggesting an "outperform" rating. The aggregate of these various perspectives grants SGMO a consensus rating of "Hold" with an average price target hovering around $4.68, as compiled by MarketBeat.com.

Market Performance of SGMO

The SGMO stock opened trading at $0.30 on the aforementioned Friday. With a market capitalization of $52.69 million, the company's fifty-day moving average stood at $0.64, and the two-hundred-day moving average was at $1.02. The biopharmaceutical company has registered a tumultuous twelve-month low of $0.30 and managed a high of $4.22 within the same timeframe.

Institutional Investment Dynamics

Key financial institutions have been adjusting their stakes in SGMO. UBS Group AG UBS, an influential global financing advisory and solutions provider, enhanced its holdings in SGMO by 670.3%, currently owning 745,980 shares valued at approximately $448,000. In the mix, Charles Schwab Investment Management Inc. SCHW, a prominent provider of banking and wealth management services, increased its share count by 27.6% to 1,191,202 shares worth roughly $714,000. Additionally, institutional investors cumulatively claim ownership of 59.81% of SGMO's stock.

About SGMO Therapeutics

Sangamo Therapeutics, Inc. is at the forefront of creating cutting-edge treatments for serious diseases in the United States. Their lead product candidates include ST-920 for treating Fabry disease, TX200 for preventing rejection in kidney transplantation, and SB-525 for hemophilia A. They are also advancing BIVV003 for sickle cell disease. All of these are in various stages of clinical trials from Phase 1/2 to Phase 3, showcasing the company's commitment to innovation in the biomedical field.

stock, analysis, investment